The prevalence of DICER1 pathogenic variation in population databases

Abstract

The DICER1 syndrome is associated with a variety of rare benign and malignant tumors, including pleuropulmonary blastoma (PPB), cystic nephroma (CN) and Sertoli-Leydig cell tumor (SLCT). The prevalence and penetrance of pathogenic DICER1 variation in the general population is unknown. We examined three publicly-available germline whole exome sequence datasets: Exome Aggregation Consortium (ExAC), 1,000 Genomes (1,000 G) and the Exome Sequencing Project (ESP). To avoid over-estimation of pathogenic DICER1 variation from cancer-associated exomes, we excluded The Cancer Genome Atlas (TCGA) variants from ExAC. All datasets were annotated with snpEff and ANNOVAR and variants were classified into four categories: likely benign (LB), unknown significance (VUS), likely pathogenic (LP), or pathogenic (P). The prevalence of DICER1 P/LP variants was 1:870 to 1:2,529 in ExAC-nonTCGA (53,105 exomes) estimated by metaSVM and REVEL/CADD, respectively. A more stringent prevalence calculation considering only loss-of-function and previously-published pathogenic variants detected in ExAC-nonTCGA, yielded a prevalence of 1:10,600. Despite the rarity of most DICER1 syndrome tumors, pathogenic DICER1 variation is more common than expected. If confirmed, these findings may inform future sequencing-based newborn screening programs for PPB, CN and SLCT, in which early detection improves prognosis.

Keywords: DICER1; DICER1 syndrome; Sertoli-Leydig cell tumor; pleuropulmonary blastoma; prevalence estimates.

Conflict of interest statement

Conflict of Interest: The authors declare no relevant conflicts of interest.

© Published 2017. This article is a US Government work and, as such, is in the public domain of the United States of America.

Figures

Figure 1. Schematic for DICER1 variant classification

Variants are classified into pathogenic, likely pathogenic, variant of uncertain significance (VUS), or likely benign depending on type of variants, metaSVM, REVEL, and CADD prediction, and any previous, published report. Type of variant was based on the canonical transcript NM_177438.2.